التفاصيل البيبلوغرافية
العنوان:
Darunavir/ritonavir monotherapy at a low dose (600/100 mg/day) in HIV-1-infected individuals with suppressed HIV viraemia
المؤلفون:
Ruxandra Calin , Fabienne Caby , Gilles Peytavin , Marc-Antoine Valantin , Lambert Assoumou , Luminita Schneider , Sophie Seang , Minh Patrick Lê , Thuy Van Nguyen , A G Marcelin , Cathia Soulié , Roland Tubiana , Christine Katlama
المصدر:
The Journal of antimicrobial chemotherapy . 73(2)
سنة النشر:
2017
مصطلحات موضوعية:
0301 basic medicine , Microbiology (medical) , Male , medicine.medical_specialty , Sustained Virologic Response , Anti-HIV Agents , 030106 microbiology , Human immunodeficiency virus (HIV) , HIV Infections , Drug resistance , medicine.disease_cause , Gastroenterology , 03 medical and health sciences , 0302 clinical medicine , Internal medicine , Drug Resistance, Viral , medicine , Humans , Pharmacology (medical) , 030212 general & internal medicine , Dose Reduced , Darunavir , Pharmacology , Ritonavir , business.industry , virus diseases , Lopinavir , Middle Aged , Viral Load , Atazanavir , Infectious Diseases , Treatment Outcome , HIV-1 , Female , business , Viral load , medicine.drug
الوصف:
Background Darunavir/ritonavir is a potent PI with a high genetic barrier and pharmacological robustness favourably investigated as monotherapy. Whether darunavir could be dose reduced in the context of monotherapy deserves investigation. Methods Patients with HIV suppressed viraemia (plasma viral load
تدمد:
1460-2091
الوصول الحر:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e568e8125602e9a26935fca0e1be5a3cTest https://pubmed.ncbi.nlm.nih.gov/29216346Test
حقوق:
OPEN
رقم الانضمام:
edsair.doi.dedup.....e568e8125602e9a26935fca0e1be5a3c
قاعدة البيانات:
OpenAIRE
